Massachusetts Begins Cannabis Retail Licensing Process

More than a year after legalizing recreational marijuana, Massachusetts begins cannabis retail licensing process today. The state Cannabis Control Commission will be accepting applications for cannabis business licenses in anticipation of legal retail sales later this year. Massachusetts voters legalized recreational pot in 2016.

Activists and regulators alike are enthusiastic about the opening of the permit process. Lester Grinspoon is a former professor of psychiatry at Harvard. He has been a leader in the struggle for legal cannabis in Massachusetts since the 1970s. And at 89 years old, he wasn’t sure he’d be around to see it.

“I speculated this could happen, but I never dreamed that I would live to see it. It certainly is gratifying,” Grinspoon told the Boston Globe.

The progress also pleased Steve Hoffman, the chairman of the cannabis commission.

“It’s an exciting step. It’s starting to become real,” he said.

State Taking Applications In Three Phases

The Cannabis Control Commission will be accepting applications for cannabis business permits in three phases. The first phase includes existing medical marijuana dispensaries and companies known as “economic empowerment applicants.” These are businesses who employ, benefit, or are owned by members of communities disproportionally affected by the War on Drugs.

Jim Borghesani is a spokesman for Regulate Mass, an activist group working to have cannabis regulated like alcohol in Massachusetts. He told local media the state is giving these companies priority in an attempt to address and compensate for past inequities in enforcement.

“A lot of these are urban areas where people were adversely impacted by prohibition because of the disproportionate number of arrests for people of color compared with people who are Caucasian,” Borghesani said.

The commission will begin accepting applications for the first phase on April 16.

Cultivators and certain small business can then submit applications beginning May 1. Manufacturers, distributors, and retail stores can apply for their licenses starting on June 1.

Regulators expect that retail cannabis sales will begin in Massachusetts sometime after July 1.

It isn’t easy for a company to successfully navigate the state’s cannabis application process. Strict regulations require applicants to submit a minutely detailed operations plan.

“You have to show a good business plan, a level of security that’s acceptable to the Cannabis Control Commission, making sure there’s no diversion of product into the black market,” said Borghesani.

The process isn’t cheap, either. Applicants must pay $500 just to submit their paperwork. The licenses themselves run from $3,000 to $10,000 each. Borghesani added that cannabis business usually can not take advantage of traditional modes of financing.

“It’s a problem because it’s still illegal at the federal level, and banks are worried about losing their federal charter,” he said.

Final Hit: Massachusetts Begins Cannabis Retail Licensing Process

Some applicants have already begun t0 prepare for the application process, despite all the red tape. Norton Arbelzaez is the director of government affairs for New England Treatment Access. His company operates a growing operation in Franklin, Massachusetts and medical marijuana dispensaries in Brookline and Northampton. The firm has already prepared its application, he reports.

“We’ve got our incorporating documents, financial statements, operating agreements — all that stuff — ready to go,” he said.

Weekly Legislative Schedule: Marijuana Bills in CO, CA, and NJ, Get Hearings

Colorado lawmakers schedule a hearing on consumption club licenses for Tuesday; two California bills will also go before a committee this week, the first proposes banning certain types of butane sales, the second seeks to unbind hemp’s restrictive definition. And in New Jersey, another bill considers removing their 2-ounce limit for medical marijuana.

It’s Springtime in North America – and the fluctuation of political might is on full display. As Trump hunkers down for another Stormy week and Ted Nugent lashes out at the Parkland teens for speaking truth to power, this week’s legislative efforts to reform America’s marijuana laws seems … perfectly logical by comparison.

Colorado

A bill to create public consumption licenses for marijuana shops in Colorado will receive a hearing on Monday before the Senate Business, Labor, and Technology Committee. First assigned to the committee on March 19, Senate Bill 211will be heard at noon in committee room 271.

Co-sponsored by State Sen. Vicki Marble (R-23rd District) and Rep. Jovan Melton (D-41st District), the bill proposes to allow licensing for individuals who operate retail marijuana shops. Under the proposed bill, those licensed for public consumption would be prohibited from serving prepared food or alcohol on-site. All marijuana products consumed on-site would need to be purchased from the licensed marijuana business/club for individuals over 21. In other words, patrons would be prohibited from bringing their own supplies.

California

California AB 3112 was introduced by Assemblyman Tom Grayson (D- 14th District) and is scheduled for hearing at 9 a.m. April 3, before the Assembly Public Safety Committee. Held in room 126 at the state capitol, the committee will consider the bill’s proposal to institute new state regulations for the restricted sale of butane. While the sale of small canisters utilized for personal lighters would still be considered lawful, the sale of larger canisters would be deemed unlawful under this proposed legislation. According to California Assembly Bill 3112, anyone who violates the proposed legislation would face a civil penalty of $2,500.

California Senate Bill 1409, a bipartisan bill that proposes changes to California’s industrial hemp laws, will receive a hearing at 9:30 p.m. March 3 before the Senate Agriculture Committee. SB 1409 suggests the deletion of an exclusionary mandate that industrial hemp seed growers be certified on or before January 1, 2013. Furthermore, the bill proposes to modify the current and restrictive definition of “industrial hemp.” Under Chapter 1 of the California Uniform Controlled Substances Act, industrial hemp is strictly viewed as a “fiber or oilseed crop.” This legislation would nullify and remove the requirement that industrial hemp be cultivated as a fiber or oilseed crop only. Ostensibly, this bill could allow California’s industrial hemp growers to utilize their harvest for the production of hemp-derived CBD products.

New Jersey

In New Jersey, A 3421, seeks to remove the current 2-ounce limit and expands access to edibles and oils. Designated as “Jake Honig’s Law,” this legislation will receive a hearing at 7 p.m., March 5, before the Assembly Appropriations Committee.

The legislation stipulates that alternative treatment centers may make medical marijuana available to patients in oil form, removes a restriction that made edible forms of medical marijuana available only to qualifying patients who are minors, and removes the current 2-ounce limit on the quantity of medical marijuana that may be dispensed in a 30-day supply. Additionally, the bill proposes authorizing a patient’s physician be allowed to recommend “medical marijuana in any quantity” for their 30-day supply. And if the recommending physician fails to specify a quantity, “the amount dispensed will be at the discretion of the alternative treatment center,” according to the proposed legislation.

Also on the calendar this week

Marijuana legislation introduced to the 2018 Connecticut General Assembly will receive a public hearing on Tuesday at noon. House Bill 05582 provides for the taxation of retail marijuana products, after legalized sales are authorized. HB 05582 will receive a public hearing before the Finance, Review and Bonding committee.

Legislation introduced in Tennessee seeks to enact the “Medicinal Cannabis Act” and would establish a medical marijuana commission for the regulation of cannabis-related healthcare. Tennessee Senate Bill 1710 is scheduled for a Senate Judiciary Hearing March 3, at 1 p.m. in the Cordell Hull Building.

On March 4 at 10:30 a.m., two Hawaiian bills will be heard in conference room 211 by the Senate Ways and Means committee. Hawaii House Bill 2741 proposes making the cost of medical cannabis a reimbursable expense to be covered by health insurance companies, and House Bill 2742 seeks to establish the Office of Medicinal Cannabis Control and Regulation within the state’s Department of Health. The proposed legislation would designate the Office of Medicinal Cannabis Control to regulate and administer the registration of qualifying patients and primary caregivers –  and all medical marijuana dispensaries.

Studies Link Legal Marijuana With Fewer Opioid Prescriptions

 Can legalizing marijuana fight the problem of opioid addiction and fatal overdoses? Two new studies in the debate suggest it may.

Pot can relieve chronic pain in adults, so advocates for liberalizing marijuana laws have proposed it as a lower-risk alternative to opioids. But some research suggests marijuana may encourage opioid use, and so might make the epidemic worse.

The new studies don’t directly assess the effect of legalizing marijuana on opioid addiction and overdose deaths. Instead, they find evidence that legalization may reduce the prescribing of opioids. Over-prescribing is considered a key factor in the opioid epidemic.

Both studies were released Monday by the journal JAMA Internal Medicine.

One looked at trends in opioid prescribing under Medicaid, which covers low-income adults, between 2011 and 2016. It compared the states where marijuana laws took effect versus states without such laws. The comparison was done each quarter, so a given state without a law at one point could join the other category once a law kicked in.

Results showed that laws that let people use marijuana to treat specific medical conditions were associated with about a 6 percent lower rate of opioid prescribing for pain. That’s about 39 fewer prescriptions per 1,000 people using Medicaid.

And when states with such a law went on to also allow recreational marijuana use by adults, there was an additional drop averaging about 6 percent. That suggest the medical marijuana laws didn’t reach some people who could benefit from using marijuana instead of opioids, said Hefei Wen of the University of Kentucky in Lexington, one of the study authors.

The other study looked at opioid prescribing nationwide for people using Medicare, which covers people 65 years or older and those with disabilities. Every year from 2010 through 2015, researchers compared states with a medical marijuana law in effect to those without one. Fourteen states plus the District of Columbia had such a law from the beginning of that time; nine other states joined them during the years the study covered.

Researchers found that Medicare patients in states with marijuana dispensaries filled prescriptions for about 14 percent fewer daily doses of opioids than those in other states. Patients in states that only allowed them to grow pot at home showed about 7 percent fewer doses.

W. David Bradford, an economist at the University of Georgia in Athens who’s an author of the second study, said the results add to other findings that suggest to experts that marijuana is a viable alternative to opioids. The weight of that evidence is “now hard to ignore,” said Bradford, who said he thinks federal regulations should be changed to allow doctors to prescribe marijuana for pain treatment.

The two studies have some limitations, Dr. Kevin Hill of Harvard Medical School and Dr. Andrew Saxon of the University of Washington in Seattle wrote in an accompanying editorial.

For one thing, they don’t reveal whether individual patients actually reduced or avoided using opioids because of the increased access to marijuana. The findings in Medicaid and Medicare patients may not apply to other people. And the results may have been skewed by some characteristics of the state populations studied, they wrote.

They called for states and the federal government to pay for more studies to clarify the effect of marijuana use on opioid use, saying such research is needed for science to guide policy-making.

Follow Malcolm Ritter on Twitter at @MalcolmRitter. His recent work can be found here.

The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

This City in Canada Wants To Ban All Public Cannabis Consumption

Months away from national legal recreational marijuana, this city in Canada wants to ban all public cannabis consumption. Lawmakers in Calgary, the capital and largest city in Alberta, and hoping to pass a bylaw that would only allow marijuana smoking indoors.

The Bylaw: What We Know So Far

If approved, Calgary residents would face $50 to $100 in fines in caught smoking marijuana outside. The only place where residents would be able to consumer cannabis would be a private home.

If passed by a council committee, this law would strictly limit legal cannabis consumption. If you live in an apartment or don’t own your home, you may not be able to smoke indoors in the first place.

This legislation would not apply to those with medical marijuana licenses or to specifically designated ‘cannabis gardens’. The concept behind these spaces is similar to a beer garden. They will also be strictly regulated.

So far, the rule for a cannabis smoking area is that it has to be separate from beer and cigarette designed areas.

You’ll also have to bring your own weed because Alberta law dictates that you can’t smoke cannabis in the same place where you bought it.

The Problem With Banning Outdoor Cannabis Use

This law will be difficult, and probably costly, to enforce. How do you distinguish between medical and recreational users? To police everyone smoking marijuana outside will require more police and more government funds.

Les Hagen, described as a tobacco control advocate by the Calgary Herald, argues, “We think it’s [the bylaw] impractical. It’ll lead to widespread violations and stigmatization as well. Anyone who is using cannabis in public, it will be seen as breaking the law.”

Not only does would this legislation be difficult to enforce, but it would also stigmatize a substance that will be completely legal by the end of the summer. This is just one example of how provincial governments are discriminating against cannabis, despite upcoming legalization.

Others are critiquing this measure for unjustly limited legal cannabis consumption for those living in shared spaces and for those who do not own homes.

Even Those Supporting This Legislation See Its Flaws

City Council member Shane Keating supports this legislation but believes that the city should create spaces for outdoor marijuana use. Keating explains, “I have no sympathy for those who deem that they have to smoke cannabis regardless of how it affects others around them.”

This does not, however, mean that Keating is completely against cannabis. He believes that edibles and inhalers are a better solution, though the former won’t be legal until 2019.

Keating is in favor of cannabis-specific locations, describing, “There may need to be certain places where you consume it like a lounge.” This sort of policy is already in place in Ontario.

Marijuana Divides Calgary Residents

This city in Canada wants to ban all public cannabis consumption, though its residents are conflicted on the matter. In a report on cannabis published in February, 55 percent of Calgary residents surveyed supported regulating marijuana like alcohol. This would mean barring public consumption. Only 32 percent voted to treat cannabis like tobacco in public places.

Contrastingly, 43 percent those surveyed in late 2017 voted to permit outdoor cannabis use. 19 percent of Calgary residents in that survey hoped that cannabis would be controlled like alcohol.

Final Hit: This City in Canada Wants To Ban All Public Cannabis Consumption

Next week, a committee will decide on the legislation that would ban public marijuana consumption in Calgary.

Considering the restriction already placed on indoor cannabis consumption, some are saying that this bylaw is impractical. It would also be a step in the wrong direction in terms of cannabis tolerance.

With Calgary residents divided on the issue of outdoor smoking, we’ll have to wait and see what happens next week.

What is BHO?

BHO stands for butane hash oil. It is a potent form of cannabis concentrates that comes in various consistencies including budder, shatter, wax and more. The name comes from the fact that butane is the solvent used to extract the oils from cannabis.

There are dangers involved with using butane to extract, including a risk of explosion. Not to mention, any pesticides, mold or other contaminants that were in the processed weed will end up concentrated in the extract. This means there are risks to both extractors and consumers.

To ensure your safety, the task of making BHO is best left to experts with the proper materials and equipment. There are a lot of errors that can be made during the extraction process that will lead to contaminants in the extract even if the flower used was clean. So if you are a consumer, you’ll want to make sure your butane hash oil is coming from a reliable source.

How Is It Extracted?

Plant material is loaded into a tube and it is soaked in butane as a solvent to separate the oils out. However, there are more than one ways to make butane hash oil.

Open Blasting

 The Glass Underground

The original method of making BHO, which commercial extractors have stepped away from, is called open blasting.

Open blasting is an outdated technique that is considered both dangerous and wasteful. The danger comes from the fact that there is nothing to contain the flammable solvent. As a result, any ignition near where you are open blasting will result in a fiery explosion.

Closed-loop

 Best Value Vacs

There are advantages of closed-loop systems other than having no openings for flammable gas to leak out of. All solvents are filled into a pressurized tank then attached to the extraction tube where all the plant materials are held. It’s worth noting that even though a closed-loop system is safer than open blasting, safety checks, precautions and measures must be taken to ensure nothing goes wrong. Seemingly small issues like a blown gasket can cause much larger issues.

The next advantage is the fact that solvents can be reused. Residual solvents collect in the recovery tank where they can be stored and recycled.

How To Consume It

Consider this a warning, if you are not a heavy cannabis consumer and you have no experience with cannabis concentrates, start slow. They call consuming extracts “doing a dab” for a reason. You only need a “dab” or a small amount to feel the potency.

The most common way to consume BHO is with the assistance of a torch flame, dab rig and nail. Most modern concentrate users prefer low temp dabbing with the addition of a carb cap. E-nails are a great way to enjoy the advantages of low-temperature dabbing without the need for a torch or butane. An e-nail usually consists of two parts: the controller where you can adjust the temperature and the heating element that wraps around a nail.

When BHO first gained popularity, titanium nails were used to drop super hot dabs, seconds after the nail is torched. Since then, dabbing has evolved to more effectively vaporize cannabis oils with minimal compromise to the flavor.

Low Temp Dabbing

Low-temperature dabs involve getting your nail about as hot as can be and waiting for it to cool before dropping the extract in.

Depending on your specific nail and the amount of time you spent heating, you can wait anywhere from about 20 seconds to over a minute. It all depends on how much heat the nail can retain. Once the nail is cool enough to vaporize the oil without completely burning the terpenes and cannabinoids away instantly, it’s safe to drop the dab.

Add the carb cap once the extracts have melted onto the nail. If it was harsh and burnt tasting, with stickiness to your lips or teeth, you went in too hot. If it was smoother and more flavorful than a high-temperature dab, you did it right and there should be some leftover oil to Q-tip up. You have to constantly clean your nails if you want to keep the flavors prominent and maximize vaporization.

Quartz Insert

@hollyhoodbambam

The next step in the evolution of low temp dabbing is the quartz insert. Quartz inserts take things a step further by forcing the concentrates to rapidly go from a low-temperature to a higher one. This allows you to experience cannabinoids and terpenes at a temperature that you previously couldn’t with a nail and cap alone.

Quartz inserts come in different shapes and sizes. The ones we are talking about are in the shape of cups that fit into any of the best quartz bangers on the market.

To taste as much of your terpenes as possible while maintaining a constant level of vaporization, we recommend trying the insert drop technique. Pre-fill the insert with your concentrate and set it aside.

Next, heat up the banger for about a minute all around. Depending on your bangers heat retention and the size of your dab, you can drop the insert in 5 to 30 seconds after you cut the torch flame. Bigger dabs should be dropped sooner. Wait a little longer on fresh nails with thick quartz.

Different Consistencies Of BHO

There are over a dozen different kinds of cannabis concentrates. Even if you use butane every time, the consistency of the material will vary. This is due to the material and techniques utilized during the extraction process. Many look like wax while others have a glassier appearance.

Oil

Oil is what we call the loosest consistency of butane hash oil. It’s sticky and only a bit thicker than a liquid. Oils that are slightly thicker than normal are called saps. Oils and saps are difficult to handle compared to other consistencies. As a result, they have become one of the least popular forms of BHO on the market.

Budder

Budder is a consistency that can be attained by introducing agitation during the extraction process. The name comes from the fact that it is similar in consistency to butter. It looks a little wet and it can be easily scooped and spread. There’s no real advantage to having a budder over a crumble or shatter. It all depends on preference. Wax pen users might prefer budder, crumble or shatter over a sappier oil.

Crumble

Crumble is named after the fact that it crumbles like dry cheese when you scoop some. Everytime you scoop from a wad of crumble, tons of tiny bits that are harder to scoop up break off. Crumble easier to handle than oils but less desirable than budder and shatter.

Shatter

Shatter is pretty much the only form of cannabis concentrate that can be handled without the assistance of a tool. The name comes from the fact that it shatters like glass. In fact, the real glassy stuff will end up breaking and flying off with a tool. Shatter can come in a looser “pull ‘n snap” consistency which is easier to handle with a tool.

Live Resin

Live resin concentrates are almost always made with butane. They differ from other extracts because of the material used. Nugs or trim that was just harvested and cryogenically frozen is used in the extraction process. They can take on different consistencies including THCa crystalline, sauce, sugar, shatter and budder.

Final Hit: What Is Butane Hash Oil (BHO)?

Butane hash oil is the most common method of making cannabis extracts. Most of the concentrates on the shelves of dispensaries are made with it. If you’re not comfortable with consuming or working with hydrocarbons, there is a cheap, easy and non-explosive way to make dabs at home called the rosin technique. Extractors can also make hash without putting themselves at risk of physical harm. Combine the rosin technique with hash making techniques to end up with connoisseur-quality products like live rosin.

Legal Medical Marijuana In South Carolina Is Closer Than Ever

In major medical cannabis news out of South Carolina, a bill that would legalize the drug for seriously ill patients made it out of committee on Thursday and will soon be under consideration in the full Senate. Now that it’s possible for the bill to get a floor vote in both chambers before the end of the current session, legal medical marijuana in South Carolina is closer than ever.

South Carolina’s Compassionate Care Act Clears Committee

On Thursday, the Senate Medical Affairs Committee voted to approve S 212, a bill that would grant qualifying patients access to medical cannabis with a physician’s recommendation.

Next up, the bill will face consideration before the full Senate. It will very likely come to a floor vote before the current legislative session’s April 10 deadline.

S 212 would task the Department of Health and Environmental Control with regulating and licensing cultivators, processors, dispensaries, and testing labs. Additionally, the department would establish a patient and caregiver registry and distribute registration cards to those enrolled.

The Compassionate Care Act, however, prohibits patients from smoking medical cannabis. For patients, the herbaceous form of cannabis is the most cost-effective, but dosing can be more challenging. Healthcare professionals also view smoke inhalation as a health hazard.

Law Enforcement Lobbying Hobbles South Carolina’s Medical Marijuana Bill

Other restrictions in S 212 would make South Carolina’s one of the most carefully regulated medical cannabis programs in the country. Those restrictions are the result of lobbying efforts by some in law enforcement.

As a result, legislators introduced several additional safeguards and amendments to address law enforcement concerns. And that has upset many supporters of the bill. They feel lawmakers are caving to pressure from police and ignoring testimony from prominent medical professionals.

Other law enforcement officials, however, have spoken out in favor of S 212. Jeff Moore, former executive director of the South Carolina Sheriffs’ Association, said: “it is presumptuous, irresponsible, and arrogant for law enforcement officials to take it upon themselves to determine what medical resources should be available for the citizens of South Carolina who are suffering and in need of relief.”

Indeed, State Law Enforcement Division Chief Mark Keel has made repeated statements claiming marijuana has no medical value. He also vowed not to support any legislation that went against the federal ban on cannabis.

The bill’s supporters, like Moore, have criticized Keel for “hiding behind dubious federal policy.”

Moore’s son, a combat veteran, uses medical cannabis to treat his PTSD. He lives in Michigan, one of the 29 states, along with D.C., Guam, and Puerto Rico, with legal medical cannabis.

So while medical marijuana in South Carolina is closer than ever before, advocates will likely have to continue to struggle to expand access for ill patients.

State representatives who support the bill have broad public support. According to a September 2016 poll, 78 percent of South Carolina residents approve legalizing medical cannabis.

The Final Hit: Legal Medical Marijuana In South Carolina Is Closer Than Ever

Despite the Compassionate Care Act’s progress, there’s still a chance the bill won’t make it out of the legislature this session.

The Senate is moving forward.

But the House has so far declined to hear its own version of the medical cannabis bill. And that could mean it stalls on S 212. The deadline for S 212 to advance is April 10.

Alzheimer’s Patients in Puerto Rico May Get Cannabis-Based Treatment

Alzheimer’s patients in Puerto Rico may get cannabis-based treatment that would make them the first in the United States with access to a new cannabinoid medicine. The development could be a big step for Puerto Rican Alzheimer’s patients in particular and for medical marijuana more generally.

Hyalolex In Puerto Rico

According to a recent press release, medical marijuana dispensaries in Puerto Rico will start carrying a product called Hyalolex as soon as April. The product is a cannabinoid-based medicine aimed at helping patients cope with the side effects of Alzheimer’s disease.

Hyalolex is manufactured by cannabis pharmaceutical company IGC. The company’s new product will hit dispensaries in Puerto Rico as part of a larger deal between IGC and DaMa Pharmaceuticals.

Under the arrangement, DaMa will play a part in manufacturing Hyalolex in Puerto Rico. From there, the companies will market Hyalolex to the 30 or so dispensaries currently operating in Puerto Rico. The product will also be marketed directly to consumers.

“We are very pleased to work with the DaMa Pharmaceutical team to bring Hyalolex to Puerto Rico, which has a long history of developing premier pharmaceutical products,” said Ram Mukunda, CEO of IGC. “We are proud to be a contributor to Puerto Rico’s economic development and to the well being of its Alzheimer’s patients.”

Hyalolex is a liquid form of medicinal cannabis. More specifically, it was designed to reduce the buildup of certain compounds in the brains of people with Alzheimer’s.

So far, the company claims that Hyalolex has shown to effectively treating a range of Alzheimer’s symptoms, including stress, anxiety, agitation, sleep disorders, and more.

Cannabis and Alzheimer’s

Hyalolex aside, cannabis has shown great promise at helping those with Alzheimer’s. In a groundbreaking 2006 study, researchers found that THCcould have positive effects on those living with Alzheimer’s. In particular, this project found that THC could slow the formation of the plaque that typically accumulates in the brains of Alzheimer’s patients.

That initial finding has set the tone for several other studies. Most recently, scientists published a paper last year that looked at the impact of small THC doses on Alzheimer’s patients. This study found that THC can slow the production of beta-amyloid proteins in the brain.

In a healthy brain, those proteins are naturally broken down. But when a person develops Alzheimer’s, those same proteins build up to create clusters of plaque. Researchers believe that these plaque build-ups play a key role in the progression of Alzheimer’s.

Fortunately, cannabinoids such as THC appear to slow this process. In particular, cannabis can help take over the task of breaking apart those beta-amyloid proteins, thereby contributing to better brain health.

Final Hit: Alzheimer’s Patients in Puerto Rico May Get Cannabis-Based Treatment

Puerto Rico already has a relatively strong medical marijuana program. There are reportedly 30 dispensaries already operating on the island. In particular, the capital city of San Juan boasts a couple well-established dispensaries.

Medical marijuana patients with Alzheimer’s are about to have access to another potentially powerful form of treatment. As research indicates, cannabis continues showing promise as a powerful way to decrease the side effects of Alzheimer’s disease.

Woman Accused of Running A Cannabis Empire Sues California City

In California cannabis news: A woman accused of running a cannabis empire sues California city for creating cannabis monopolies. Months after the police shut down and raided her grow house that allegedly made millions per month, Stephanie Smith asserts that San Bernardino’s new marijuana licensing ordinance is unfair to certain cannabis businesses.

The Massive Grow House

Last December, Stephanie Smith became famous for her ‘weed fortress‘ in San Bernadino. After locals complained to police and authorities discovered that a ‘derelict’ warehouse was paying $67,000 per month for electricity, the police began an investigation.

What the police found was a massive grow facility. Someone had installed a twelve-foot fence, concrete walls, a high tech surveillance system and fortified doors.

Not only that, but the police seized 35,000 marijuana plants, which amounts to 18,000 pounds. San Bernadino police officer Mike Madden told CBS News, “In my 26 years, it was the biggest grow that I’ve ever seen.”

Authorities Have Not Charged Smith

Despite her connection to the grow house, Stephanie Smith has not charged with a crime. The mother of five has positioned herself as a real estate developer, rather than a cannabis grower. Smith claims that she rents the space to tenants who grow commercial cannabis.

Her lawyer said, on her behalf: “I am a well-known and recognized leader in large-scale cannabis real estate development and I am proud of the State of California’s position on cannabis.”

Though Smith hasn’t faced any charges, eight grow house employees were initially arrested.

Smith Is Suing San Bernardino

A few months after the police raided these massive weed facilities, this woman accused of running a cannabis empire sues California city. This month, San Bernardino approved a regulation that only allows the city to issue 17 cannabis business licenses in the first year of legalization. It also prevents any marijuana businesses categorized as in conflict with authorities from qualifying for such a license. This violates California’s Prop. 64 according to Smith.

Smith explains that San Bernardino’s new regulation will prevent “any person who has ever had anything to do with cannabis … from entering the legal market,” thus creating monopolies.

Smith has allegedly operated her grow facility without any permits. Despite the lack of charges levied against her, she wouldn’t qualify for such a license from the city of San Bernardino. Authorities still perceive Smith as being in opposition to the law.

Other Cities in California Are Helping, Not Hindering, Those Convicted of Marijuana Possession

San Bernardino’s cannabis legislation is markedly different from Oakland and Los Angeles’ policies. These two cities are giving opportunities to those with cannabis convictions. San Bernardino, on the other hand, is preventing their involvement in legal weed business.

While this isn’t necessarily illegal, it continues the legacy of the war on drugs. By preventing those with weed convictions for operating legal establishments, San Bernardino is discriminating against minorities, who are much more likely to have been arrested for weed.

Are Smith’s Claims Valid?

Potentially. One of the tenets of Prop 64 is that you can get your record expunged for certain marijuana possession. Though San Bernardino has not charged Smith with anything, this new ordinance could potentially contradict Prop 64’s focus on ending discrimination against those caught with marijuana.

Final Hit: Woman Accused of Running A Cannabis Empire Sues California City

The alleged proprietor of San Bernardino’s weed empire is suing the city for their new cannabis business ordinance. This isn’t the first California lawsuit involving marijuana: The famed California cannabis church is suing the police.

Though the lawsuit’s outcome isn’t definite, it will certainly shed light on San Bernardino’s controversial marijuana laws, and make Stephanie Smith even more of a weed celebrity.

Landlord Sues San Bernardino Over Marijuana Regulations

LOS ANGELES (AP) — A woman who owns a business that claims to be California’s largest landlord of marijuana businesses sued the city of San Bernardino to overturn its pot regulation ordinance that could bar her from the industry.

Stephanie Smith, the owner of a business called Bubba Likes Tortillas, said in the lawsuit filed Friday in San Bernardino County Superior Court that the city’s new law could create monopolies and also prevent her from renting property to pot growers and other marijuana operations.

The dispute dates back to December when a fortified building Smith owns was raided, cultivation operations her clients were operating were shut down and 35,000 marijuana plants were seized. Smith was not involved with pot growing and she was not arrested or charged, her attorney Ben Eilenberg said.

After the raids, a judge invalidated a voter-approved measure to regulate marijuana operations and San Bernardino City Council passed its own measure to replace it earlier this month.

The new rules said anyone — from a permit applicant or an employee of a cannabis business to the owner of a property — could be barred from the commercial cannabis business in the city if they had violated local or state laws related to the industry or if they had failed to report income from it.

Smith is concerned that could apply to tenants — or even her company — because the businesses raided in December were in the process of being licensed, Eilenberg said. They received approval letters to operate a week after they were shut down, but the law appears to make them ineligible to get licenses.

“This misguided ordinance is a backdoor ban that continues the city’s illogical campaign against a legal product,” Smith said in a statement. “Any person who has ever had anything to do with cannabis is banned for life from entering the legal market under this ordinance. It is not what the voters want and it makes no sense.”

Eilenberg said it could also apply to businesses that operated in the murky days when medical marijuana was loosely regulated. Cities like Los Angeles and San Francisco have given priority to license businesses that operated under medical marijuana regulations to get into the broader retail market that opened Jan. 1.

“San Bernardino is taking the opposite tack and guaranteeing that anyone in the city who operated prior to this law has to remain in the black market,” Eilenberg said.

The lawsuit said the ordinance would violate the constitutional right to due process by disqualifying tenants or Smith without ever granting them an administrative or criminal hearing.

The lawsuit also claimed the city law could create monopolies of certain types of marijuana operating licenses.

The ordinance would allow 17 commercial marijuana businesses in the city, but there are 19 different types of licenses that could be issued — everything from growing pot, to transporting it, testing it and selling it.

A city spokeswoman did not immediately comment on the case.

Big Pharma Company Partners with Cannabis Producer

There has been a major new partnership formed in the pharmaceutical industry, according to a newly filed binding letter of intent. American-owned cannabis producer Tilray will form a strategic alliance with Sandoz Canada, an affiliate of Sandoz International, the arm of Novartis Group that produces generic pharmaceutical products.

This won’t be a limited partnership, either, as the two entities plan to collaborate on “all key business, supply, legal, marketing and sales aspects of the proposed alliance.”

Isabelle Troïtzky, a spokesperson for Sandoz, spoke with in-Pharma to shed light on the new joint project.

“Once the alliance is in effect, initially, Tilray capsules and ingestible oil products will be offered for sale under doctor’s authorization directly to patients in Canada via mail order,” explained Troïtzky.

“Subject to future regulatory changes, Sandoz Canada will wholesale and distribute co-branded — Sandoz and Tilray — non-smokable/non-combustible medical cannabis products to Canadian hospitals and pharmacies.”

Right now, medical marijuana patients in Canada can only obtain cannabis products through mail-order from a licensed producer. Tilray, an affiliate of Privateer Holdings, is likely banking on future regulation changes to allow for dispensing at pharmacies as well.

Novartis won’t be the only major pharmaceutical player to diversify their portfolio by getting involved with cannabinoid-focused properties like Tilray.

Big Pharma joining the cannabis industry instead of fighting it.

Opioid manufacturers have been entering the industry instead of fighting it. Corporations like Noramco, who was awarded two U.S. patents covering CBD and THC production, and synthetic cannabinoid maker Insys Therapeutics have both been involved in developing medical marijuana solutions.

Noramco, who has some experience with cannabis as the manufacturer of synthetic cannabinoid medication dronabinol, received patents to manufacture both CBD and THC-based products for clinical and pharmaceutical use.0327

Insys Therapeutics, the maker of a synthetic CBD oral medication that is currently in clinical trials, is also one of the most prominent manufacturers of fentanyl products in the world. Their Subsys fentanyl oral spray is at the center of a bribery scandal currently, as the company was allegedly paying doctors in New York exorbitant kickbacks to ramp up prescriptions of the deadly drug. Five doctors have been charged and Insys CEO John Kapoor and other top company executives have been indicted for their alleged involvement.

Sandoz’s parent-company Novartis has had its fair share of controversy surrounding the opioid epidemic as well.

In 2012, Novartis was embroiled in controversy when it was discovered the company neglectfully packaged prescription opioid painkillers in boxes of over-the-counter medications like Excedrin, NoDoz, and Gas-X. More than 1,600 batches of the non-prescription drugs boxed at a Lincoln, Nebraska factory that also produces dangerous and addictive opioid pharmaceuticals were recalled by the company.

The potentially fatal mistake was discovered by the Food and Drug Administration during an inspection when they found a malfunctioning element of the manufacturing process. The pills had been getting stuck and carried over into packaging for other medications.

Additionally, federal prosecutors alleged last year that Novartis was deceitful in its claims that it held nearly 80,000 “educational events” for doctors. While the company claimed it was inviting doctors from around the country to speaking engagements they said were purely educational, the government believes the “sham” events, as they call it, were merely kickbacks in nature — opportunities to treat physicians who were prescribing Novartis drugs to luxurious trips.

This month, prosecutors said they have Novartis sales reps who will testify that they were “essentially buying scripts” by lining the pockets of doctors around the nation. The government also says it has evidence doctors were paid to speak at events that never actually occurred.

Novartis, for their part, “disagrees with the government’s characterization of our conduct and continues to dispute the allegations concerning certain speaker programs.”

While some pharma companies have proved corrupt in the past, it may be imperative to include them in the progression of medical marijuana research. Between vast funds dedicated to finding new therapeutic solutions and the scientific minds to conduct new-age research, these companies could speed up the process quite a bit.

In a monumental medical marijuana summit at Harvard Medical School, Dr. Raphael Mechoulam, the founding father of cannabis research and the man who isolated cannabinoids for the first time, explained how pharmaceutical companies could help bring cannabis out of the shadows.

“People express themselves and say, we want this to be done, it can be done,” said Dr. Mechoulam. “It is complicated. It will cost money. It will take time, but it can be done.”

“I thought that as soon as we know the chemistry and the pharmacology and then the toxicity, and if there are any positive effects, companies will go in and take compounds and go ahead with clinical trials, which is true for a huge, huge number of drugs.”